Nature22h
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...
Daily6d
Phase 2b QUALITY Trial: Enobosarm Significantly Reduces Lean Mass Loss in Patients on Semaglutide
Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...